Rapid Therapeutic Science Laboratories, Inc.
RTSL
$0.0074
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 97.70K | 92.30K | 30.40K | 345.70K | 122.40K |
| Depreciation & Amortization | 6.00K | 6.00K | -57.80K | 27.30K | 6.00K |
| Other Operating Expenses | -82.50K | -- | -- | -- | -- |
| Total Operating Expenses | 21.20K | 98.30K | -27.30K | 372.90K | 128.40K |
| Operating Income | -21.20K | -98.30K | 27.30K | -372.90K | -128.40K |
| Income Before Tax | 46.40K | 191.30K | 48.90K | -227.10K | -36.80K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 46.40K | 191.30K | 48.90K | -227.10K | -36.80K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.40K | 191.30K | 48.90K | -227.10K | -36.80K |
| EBIT | -21.20K | -98.30K | 27.30K | -372.90K | -128.40K |
| EBITDA | -15.20K | -92.30K | 33.30K | -366.90K | -122.40K |
| EPS Basic | 0.01 | 0.02 | 0.01 | -0.03 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.02 | 0.00 | -0.02 | 0.00 |
| EPS Diluted | 0.01 | 0.02 | 0.01 | -0.03 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.02 | 0.00 | -0.02 | 0.00 |
| Average Basic Shares Outstanding | 8.32M | 7.98M | 7.75M | 7.75M | 7.75M |
| Average Diluted Shares Outstanding | 8.32M | 7.98M | 7.75M | 7.75M | 7.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |